Studying Childhood ALL Relapse and Survival
Name of the Trial
Why This Trial Is Important
While the rates of disease remission following initial treatment are similar for children of various racial and ethnic groups, the rates of relapse and survival differ. Asian children have the best survival and African American children the worst. Survival rates for white and Hispanic children fall between these extremes.
In this study, researchers will monitor patients in these groups to see if differences can be found in disease biology, in the way cancer-fighting medications (in particular, mercaptopurine) are metabolized by the body, and in adherence to prescribed long-term medication dosing and schedule. Blood samples will be taken to determine how children in the different groups metabolize mercaptopurine, because differences in drug metabolism may contribute to the dissimilarity in survival rates. In addition, an electronic pill-monitoring system and adherence questionnaires will be used throughout the study to determine if there are differences in adherence behavior.
"It is very important to understand why differences in relapse and survival exist, so we can initiate interventions to mitigate these differences," said Dr. Bhatia. "If effective interventions can be developed, survival for Hispanic and African American children could potentially improve by 10 to 15 percent."
Who Can Join This Trial
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.